secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOTRICITY INC. (BTCY)
CIK:        0001630113
Form:       8-K
Filed at:   2023-04-03T23:59:59+00:00
Accession:  0001493152-23-010668
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biotricity shareholders approve 2023 equity plans, reverse split up to 1:10, and $10M convertible note issuance
--------------------------------------------------------------------------------

- Approved 2023 Equity Incentive Plan reserving 5M shares plus any unissued from 2016 plan (15.7M votes for).
- Authorized reverse stock split within 1:2 to 1:10 ratio, with Board discretion to implement within one year (27.5M for).
- Approved potential issuance of up to $10M common stock upon conversion of convertible notes (17.3M for, 629.8K against).
- Ratified SRCO Professional Corporation as independent auditor for FY ending March 31, 2023 (28.7M for).
- Directors elected: Waqaas Al-Siddiq, David A. Rosa, Ronald McClurg, Chester White.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630113/000149315223010668/0001493152-23-010668-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630113/000149315223010668/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-010668

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer